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Abstract
Background: Human fasciolosis is a re-emerging disease worldwide and is caused by species of the genus Fasciola (F.
hepatica and F. gigantica). Human fasciolosis can be diagnosed by classical coprological techniques, such as the Kato-Katz
test, to reveal parasite eggs in faeces. However, although 100% specific, these methods are generally not adequate for
detection of acute infections, ectopic infections, or infections with low number of parasites. In such cases immunological
methods may be a good alternative and are recommended for use in major hospitals where trained personnel are available,
although they are not usually implemented for individual testing.
Methodology/Principal Findings: We have developed a new lateral flow test (SeroFluke) for the serodiagnosis of human
fasciolosis. The new test was constructed with a recombinant cathepsin L1 from F. hepatica, and uses protein A and mAb
MM3 as detector reagents in the test and control lines, respectively. In comparison with an ELISA test (MM3-SERO) the
SeroFluke test showed maximal specificity and sensitivity and can be used with serum or whole blood samples.
Conclusions/Significance: The new test can be used in major hospitals in hypoendemic countries as well as in endemic/
hyperendemic regions where point-of-care testing is required.
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Introduction
Fascioliosis (=fascioliasis) is a plant-borne zoonosis caused by
infection with trematode species of the genus Fasciola. Human
fasciolosis is a re-emerging disease present worldwide, and can be
produced by Fasciola hepatica and Fasciola gigantica. In Europe, the
Americas and Oceania, only F. hepatica is present, but in several
areas of Africa and Asia the geographical distribution of both
species may overlap [1] and even hybridize in some cases [2,3].
Overall, it is considered that between 2.4 [4] and 17 million [5]
people from 55 countries are infected by Fasciola species and that
180 million people are at risk of infection [1]. Fasciolosis is an
important health problem in some South American countries
(Bolivia, Peru, Chile and Ecuador), in the Caribbean (Cuba),
northern Egypt, and in the Caspian region (Iran), although human
infections by Fasciola are not infrequent in European countries
such as Portugal, Spain, France and the United Kingdom [6].
Furthermore, it is expected that this trematode-induced disease
will increase over time as a result of climate change and the advent
of milder, wetter weather [7,8].
Human fasciolosis can be diagnosed by classical coprological
techniques, such as the Kato-Katz test [9], to reveal parasite eggs
in faeces. However, although 100% specific, these methods have
some limitations including: i) non usefulness during the prepatent
period (first 3–4 months after infection [10]); ii) poor sensitivity in
patients with a low degree of parasitization, or in patients with
intermittent egg shedding; iii) non usefulness in ectopic infections
or when parasites do not reach maturity.
To avoid the above problems, some immunological techniques
based on the determination of circulating secretory antigens
[11,12], testing of coproantigens [11,13], or determination of
serum anti-Fasciola antibodies [14–18] have been reported in the
last two decades. However, for detection of early stages of Fasciola
infections in humans, or ectopic infections, antibody determina-
tions are preferable to coprological tests as circulating antibodies
are produced early on and remain detectable for long periods.
Several antigenic fractions of Fasciola [19,20], purified antigens
[21,22] and recombinant antigens [15,23,24] have been success-
fully used for the serodiagnosis of fasciolosis in human and animal
species. Nevertheless, cathepsins L are the most frequently used
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as circulating antibodies to these molecules remain at high levels
for long periods [27]. An ELISA test (MM3-SERO) that had
proven useful for serodiagnosis of fasciolosis in several animal
species with maximal sensitivity and specificity [27–30], was
recently found to involve binding to cathepsins L1 and L2 from
both species of Fasciola [31].
Despite the usefulness of serological ELISAs for the diagnosis of
fasciolosis, human infections frequently occur in non-developed
countries where access to diagnostic laboratories is not always
possible. In this sense, the development of rapid lateral flow
immunoassays (LFIAs), also known as immunochromatographic
tests, would be of great interest. In this study we report the
development and evaluation of a new LFIA for serodiagnosis of
human fasciolosis,whichcanbeusedforpoint-of-care(POC)testing.
Materials and Methods
Ethics statement
The study protocol was approved by the Ethics Committee of
the Universidad de Santiago de Compostela, Spain. The serum
samples used in this study were obtained as part of public health
diagnostic activities, were already collected before the start of the
study, and were tested as anonymous samples. Control (negative)
blood samples were obtained from volunteers after they had
provided written informed consent.
Human sera and blood samples
The serum samples (n=203) used in this study were obtained
from serum collections stored in the Centro Nacional de
Microbiologı ´a (ISCIII, Madrid, Spain), Laboratorio de Parasitologı ´a
(Facultad de Farmacia, USC, Spain), Centro de Investigacio ´n de
Enfermedades Tropicales de la Universidad de Salamanca (CIE-
TUS, Salamanca, Spain) and the Centre for Parasite Immunology
and Biology (CSPGF-INSA, Porto, Portugal). We analyzed serum
samples from 39 patients with fasciolosis, 27 patients with
schistosomosis, 20 patients with filariosis, 9 patients with hydatidosis,
15 patients with anisakiosis, 22 patients with toxocariosis, 12 patients
with Chagas’ disease, and sera from 59 patients with non-infectious
pathology (mainly from surgical interventions for non-painful
processes such as cataracts and hernias). The above infections were
diagnosed in the country of origin of the patients by one or more of
the following methods: i) routine coprological techniques for
detection of ova and parasites (Kato-Katz and Ritchie tests, using
3 stool samples), (ii) examination of urine for Schistosoma haematobium
eggs, after sedimentation, (iii) Knott’s test for detection of
microfilaremia in blood, (iv) the ICT Filariasis test (Binax, Portland
and Maine) for detection of Wuchereria bancrofti, (v) an ‘‘in house’’
ELISA test with soluble antigens present in sheep hydatidic cysts as
target [32,33], (vi) detection of IgE antibodies to the allergens Ani s 1
and Ani s 7 from Anisakis [34], (vii) Enzymun-test IgE (Boehringer-
Mannheim Lab., Mannheim, Germany) for detection of anti-
Toxocara antibodies in serum, and (viii) the Chagatest-ELISA
recombinante (Wiener Laboratorios S.A.I.C., Rosario, Argentina)
for detection of serum antibodies in Chagas’ disease.
Fasciola seropositive patients from Portugal were tested by using
Fasciola excretory-secretory antigens (ESAs) as target in ELISA
and/or by Western-blotting analysis [35], while seropositive
patients from Salamanca were tested by an ELISA test with
Fasciola ESAs, according to Hillyer et al. [36], and patients from
Madrid were diagnosed by use of a haemagglutination assay
(Fumouze Diagnostics, Paris, France). All Fasciola positive patients
from Santiago de Compostela, and the above positive sera were
confirmed for the presence of anti-Fasciola antibodies by use of the
MM3-SERO ELISA (see below).
Negative whole blood samples were obtained from 12
volunteers (8 women and 4 men, aged 20–55 years) by fingertip
puncture with a lancet (Glucoject, Menarini Diagnostics, Firenzi,
Italy), at the Faculty of Pharmacy, University of Santiago de
Compostela, Spain.
Cloning of a procathepsin L1 gene (rpCL1) from adult
Fasciola hepatica
An L1-cathepsin from F. hepatica (gb|FR848428) was cloned as
previously reported [31]. Briefly, the encoding gene without the
putative N-terminal fragment (signal peptide) was cloned into the
pQE expression vector (QIAGEN, QIAGEN Iberia S.L., Madrid)
with the primers 59-pCL1 TCGAATGATGATTTGTGGCAT-
CAGTGGAAGCG (forward) and 39-pCL1 CGGAAATCGTGC-
CACCATCGG (reverse), and further transformed into the M15
[pREP4] strain of E. coli (QIAGEN, [37]). Fasciola hepatica recom-
binant rpCL1 expression was induced by addition of 1 mM IPTG.
Purification and refolding of the rpCL1
After induction, cells were harvested by centrifugation and the
insoluble recombinant proteins were purified with B-PER reagent
(Thermo Fisher), solubilized and purified by affinity-chromatog-
raphy with HIS-Select Nickel Affinity Gel (Sigma-Aldrich) under
denaturing conditions, as indicated by the supplier (8 M urea).
The protein solution containing the rpCL1 was then refolded by
dispersing the eluate at a ratio of 1: 50 in PBS containing cysteine
(10 mM) and cystine (1 mM), followed by membrane-filtration
concentration in an Amicon Stirred Ultrafiltration Cell equipped
with a Filtron Omega Series membrane (10 K nominal molecular
weight limit; Pall Filtron Corporation). Finally, the protein
concentration was measured with the Micro BCA Protein Assay
Kit (Pierce, Rockford, IL), adjusted to 2 mg/ml in PBS, and the
sample was stored at 280uC until use.
MM3 ELISA determinations
Human serum samples were analyzed by MM3-SERO ELISA,
a capture immunoassay that detects antibodies against the highly
Author Summary
Fasciolosis is an important plant-borne trematode zoono-
sis. This disease is of both clinical and veterinary relevance
and, according to the WHO, is considered a re-emerging
disease that is spreading around the world. Fasciolosis has
a serious impact on health because of the large size of the
parasite and the effects of the parasite in down-regulating
the host immune response. Human fasciolosis can be
distinguished by an acute phase, in which the parasite
migrates through different tissues, and a chronic phase in
which it invades the bile ducts. Here we describe the
development of a rapid, simple and inexpensive immuno-
chromatographic diagnostic method, based on the use of
a recombinant cathepsin L1 protein, which performs
better than other more complex indirect methods,
providing similar specificity and higher sensitivity. The
simplicity of the method represents a great advantage for
the intervention systems applied in different endemic
areas by WHO, such as passive case finding (e.g. Vietnam)
and selective treatment (e.g. Egypt). Because of its
characteristics, the system can be applied to both phases
of the disease, and in holo, meso and hyperendemic areas
where point-of-care testing is required.
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microtitre F16 plates (Greiner Bio-One, Sigma-Aldrich, Madrid,
Spain) were coated for 2 h at 37uC with mAb MM3 (100 ml/well
of a solution containing 5 mg/ml protein in PBS), and the
uncoated sites were blocked with a 1.5% solution of buffered
sodium caseinate for 1 h at room temperature (RT). After washing
once with PBS containing 0.2% Tween-20 (PBS-T), 100 mlo f
either F. hepatica ESAs (0.4 mg/ml total protein) in PBS-T, or
100 ml of PBS only, were added to odd (Ag+) and even (Ag2) plate
rows, respectively, and then incubated for 1 h at RT. After
washing 4 times with PBS-T, 100 ml of each serum sample, diluted
1/100 in PBS-T containing 1% of skimmed milk, were added to
each Ag+ and Ag2 ELISA well, in duplicate. Plates were then
incubated for 2 h at 37uC, washed 5 times with PBS-T, and
incubated at 37uC for 1 h with 100 ml/well of anti-human IgG1
monoclonal antibody (Sigma-Aldrich) labelled with FITC and
diluted 1/3000. The reaction was revealed with peroxidase-
conjugated rabbit anti-FITC IgG (Serotec; dilution 1/5000).
Plates were washed again 5 times with PBS-T, and 100 mlo f
substrate (SigmaFast OPD, Sigma-Aldrich) were added to each
well. The plates were then incubated for 20 minutes, and the
reaction was stopped with 25 mlo f3 NH 2SO4. The optical density
(OD) was measured at 492 nm in an ELISA reader. The OD
value for each sample was calculated as OD1 minus OD2, where
OD1 is the mean for the 2 Ag+ wells, and OD2 is the mean for the
2A g 2 wells. A cut-off value of OD=0.05 for positive responses
was calculated as the OD mean plus four times the standard
deviation obtained for 200 human serum samples (age range: 20–
76 years) from patients with eosinophilia of unknown origin but
negative for Fasciola, by use of the Fumouze’s haemagglutination
test. However, to avoid false positive reactions due to batch
variations in secondary ELISA reagents, a doubtful range
(OD=0.05–0.099) was arbitrarily established for this test, while
OD values equal or higher than OD=0.1 were considered
positive.
LFIA development
Preparation of colloidal gold conjugate. The colloidal
gold conjugate used in this study was prepared with the Gold in a
Box conjugation kit (BioAssay Works, Ijamsville, MD), according
to the supplier’s instructions. Briefly, 0.5 ml samples of the
colloidal gold solution (15 OD, 40 nm) buffered in the pH range
7–10 were mixed with the solution of Fasciola rpCL1 (28 mg/ml)
and maintained at RT with some additional mixing for 30 min.
Each solution was then tested for stability by mixing 10 mlo f1M
NaCl with the same amount of gold conjugate. Once the desired
pH was selected, a batch of 40 ml gold conjugate was prepared,
with the same concentration of rpCL1 as above. The conjugate
was then stabilized with the Blocking Stabilizer Solution (provided
by the manufacturer) and allowed to stand at RT for a further
16 h. Finally, the gold conjugate was used to construct the LFIA
device.
Preparation of the LFIA strips. The LFIA device (Fig. 1)
was composed of a sample pad of cellulose fibre (CFSP203000,
Millipore Iberica SA, Barcelona, Spain), a glass fibre conjugate
pad (GFCP103000 Millipore), a nitrocellulose (NC) membrane on
a plastic back (HF135MC100, Millipore) and an absorbent
cellulose fibre pad (CFSP173000, Millipore). A solution of
1 mg/ml of recombinant Staphylococcus Protein-A (Sigma) and a
solution of 1 mg/ml of mAb MM3, both in PBS, were dispensed
in the detection and control lines of the NC membrane,
respectively, using a BioDot XYZ platform (BioDot Inc., Irvine,
CA) at 1 ml/cm. After the reagents were dispensed, the NC
membranes were dried overnight at 37uC.
The glass fibre containing the gold conjugate was prepared by
immersion of the conjugate pads in the colloidal solution and the
pads were then dried overnight at 37uC on a stainless steel mesh.
Finally, the sample pad, conjugate pad and the absorbent pad
were sequentially assembled on the NC membrane cards with a
2 mm overlap. Finally, the assembled plates were cut into 3-mm-
wide strips with a manual 550-AP Kobra Cut guillotine (Elcoman
SLR, Milan, Italy) and stored in the presence of a desiccant, at
4uC, before use.
Test procedure. To test for anti-Fasciola IgG antibodies in
serum, the sera previously diluted 1/100 in 200 ml of SeroFluke
buffer were placed in the wells of a polystyrene microtitre plate to
which the LFIA strips were applied and allowed to develop for
10 min. During the assay, the antibodies present in the sample
migrate with the buffer through the device and bind to the rpCL1-
gold conjugate forming antibody-rpCL1-gold (ACG) complexes,
which continue migrating through the NC membrane. In positive
samples, most of the ACG complexes are retained by protein A in
the NC test line producing a coloured band. The excess rpCL1-
gold conjugate with free MM3-recognizing epitopes is not retained
in the test line, and continues to migrate until reacting with MM3
mAb, which is present in the control line of the NC membrane,
thus producing a second coloured band. In negative samples, the
rpCL1-gold conjugate is not retained in the test line because the
ACG complexes are not formed, thus producing a single coloured
band (control line).
For determination of anti-Fasciola antibodies in whole blood
samples, each sample (10 ml plus 2 ml of positive serum, or 10 mlo f
blood alone) was mixed with 190 ml of SeroFluke buffer in the
microtitre well and allowed to haemolyze for 2 min. The LFIA
strips were then placed in each sample and allowed to react for
10 min as above. The strips were then cut transversally with
scissors at the starting point of the NC on each strip, and placed in
an another microtitre well containing 200 ml of SeroFluke buffer
for washing. After 10 min the results were read as for the serum
samples.
For comparison with MM3-ELISA OD values, the signals
obtained with positive sera using the SeroFluke test were classified
in arbitrary units (AUs) on a scale of 0 (negative) to 5 (strongly
positive), according to the intensity of the signal obtained in the
test and control lines of the device. The AU colour scale was
created according to the signals obtained with the pooled sera
described in Fig. 2. The following equivalence was used: AU=0
(negative); AU=1 (as for serum dilution 9); AU=2 (as for serum
dilutions 7 and 8); AU=3 (as for serum dilutions 5 and 6); AU=4
(as for serum dilutions 3 and 4; and AU=5 (as for serum dilution 1
or lower).
Figure 1. Schematic view of the SeroFluke device. A) lateral view,
B) front view. The strip components are: 1) sample pad, 2) conjugate
pad, with rpCL1 coupled to colloidal gold, 3) nitrocellulose membrane,
4) wick. The test and control lines contain recombinant Staphylococcus
protein A and mAb MM3, respectively.
doi:10.1371/journal.pntd.0001376.g001
A Serological LFIA for Fasciola
www.plosntds.org 3 November 2011 | Volume 5 | Issue 11 | e1376Results
Design and use of the SeroFluke test
The HF135 (Millipore) NC membranes, which allow flow rates
of 135634 sec/4 cms, a pad conjugate containing rpCL1 bound
to colloidal gold at pH 8.6, together with protein A in the test line,
and mAb MM3 in the control line, were used to construct a lateral
diffusion test for serodiagnosis of human fasciolosis. Typical results
for a positive and a negative serum are shown in Fig. 3. As can be
observed, both positive and negative lines were strongly coloured,
and therefore suitable for screening with the naked eye. The data
in Fig. 3 also show that negative samples produced a strong signal
in the control line with no background in the test zone.
To investigate the detection limit of the assay [38], we
compared the signals obtained with two-fold serial dilutions of
three positive pooled sera in the LFIA, with those obtained in the
MM3-ELISA used as gold standard. The data in Fig. 2 show that
the new LFIA is highly sensitive, as it was able to recognize as
positive the pooled sera at a higher dilution (dilution 9; 1/25600)
than the MM3-SERO test (dilution 7; 1/6400). With respect to the
stability of the SeroFluke test, we observed that the detection limit
did not change after storage for three months at 37uC, or 6 months
at room temperature, when the strips were maintained in plastic
bottles with a desiccant (data not shown).
Analysis of the sensitivity and specificity of the SeroFluke
test
In order to evaluate the sensitivity and specificity of the new
SeroFluke test, we compared the results obtained with this test and
the MM3-SERO ELISA test, using sera from patients positive for
fasciolosis and sera from patients with the other parasitic infections
described above. The data in Table 1 show an almost perfect
concordance of results obtained by both methods, for positive
(n=39) and negative samples (n=164). In fact, the only partial
discrepancy was one serum sample containing a very small
amount of anti-Fasciola antibodies, which tested doubtful
(OD=0.08) in the MM3-SERO ELISA and positive in the
SeroFluke test (Table 2). The mean value for the MM3-SERO
ELISA in the group of Fasciola positive sera was OD=1.61 (OD
range: 0.08–2.71), all of which produced a clear signal in the test
line of the SeroFluke device, according to the AUs scale indicated
in the Material and Methods section. The data in Table 2 also
indicate that although some positive sera produced higher signals
with SeroFluke than with MM3-SERO, more than 82% of sera
that produced strong signals in the SeroFluke test (ranks 3–5 AU)
also produced good signals (.OD=0.5) in ELISA.
Usefulness of the SeroFluke test for detection of
anti-Fasciola antibodies in whole blood
Once we had evaluated the usefulness of the SeroFluke test for
diagnosing human fasciolosis in sera, we checked the validity of the
test for diagnosing human Fasciola infection by using whole serum
samples. Because of the non availability of whole blood from
positive patients, we mixed blood samples from 12 healthy
volunteers with pooled positive or negative sera. As indicated
above, the test was run for 10 min, and the device was then
washed in fresh buffer to remove the haemoglobin, thus facilitating
the visualization of positive lines. The practical use of this test with
whole blood samples and the results obtained after the washing
step for two positive and one negative serum samples are shown in
Fig. 4.
Discussion
The SeroFluke LFIA described in this study is the first one-step
LFIA developed for serodiagnosis of human fasciolosis and, to our
knowledge, it is also the first LFIA device developed for
serodiagnosis of a trematode-induced disease. As reported above,
human fasciolosis can also be correctly diagnosed with several
ELISA tests [17,18,23], or the MM3-SERO described here, but in
general these immunoassays must be carried out in specialized
centres, by trained personnel. However, the SeroFluke test can be
used by personnel with minimal training, and more importantly, it
can be used for POC testing, which is of great importance for
medical attention of populations in several countries where this
Figure 2. Comparison of the detection limit of the MM3-SERO
and SeroFluke tests. The ability of MM3-SERO ELISA (A) and
SeroFluke (B) to detect anti-Fasciola antibodies in two fold dilutions
of pooled positive sera was compared. The starting serum dilution was
1/100 for both tests.
doi:10.1371/journal.pntd.0001376.g002
Figure 3. A typical positive and negative result with the
SeroFluke test. A strong positive signal in the test line with the
positive sample, and no signal with the negative serum can be
observed.
doi:10.1371/journal.pntd.0001376.g003
A Serological LFIA for Fasciola
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using whole blood samples for the SeroFluke test (obtained by e.g.
taking a drop of blood by fingertip puncture with a lancet, as in
this study, or even collected on filter paper [39]) is also
advantageous, as this is cheaper and saves the time and expense
involved in obtaining serum samples. However, even considering
only major laboratories in hypoendemic countries, the new LFIA
may offer advantages over ELISA methods, as it allows individual
testing of patients, whereas ELISA methods are designed to test
several patients at once and some robustness may be lost when
they are used only sporadically [40]. Furthermore, the LFIAs can
be produced in small quantities (e.g. in the range of 10–25 tests),
which would reduce the costs associated with the shelf-life of the
kits. In this respect it should be considered that the use of
serological methods to detect anti-Fasciola antibodies in non-
endemic countries is frequently limited to patients with eosino-
philia of unknown origin, or to confirm infection suspected after
radiological analysis.
In the present study, only one Fasciola serum sample tested
doubtful by MM3 SERO. The sample was obtained from a
patient who had tested positive by MM3 SERO two years before
and was subsequently treated with triclabendazole. Assuming such
serum to be truly positive, the SeroFluke test displayed 100%
sensitivity and 100% specificity. Moreover, as demonstrated by
testing serial serum dilutions (Fig. 2), the SeroFluke test showed a
lower detection limit, which enables clear positive signals to be
obtained with sera from patients with very low circulating anti-
Fasciola antibodies. The high sensitivity of the SeroFluke test was at
first glance surprising, since the sensitivity of LFIAs designed to be
read by the naked eye is often lower than the equivalent
laboratory-based ELISA tests [41]. Moreover, this may be even
more surprising if we take into account that the antigen used in the
MM3-SERO ELISA includes several L-type cathepsins (L1 and
L2) from Fasciola [29,31], whereas the SeroFluke test was
constructed with a single-labelled artificially-refolded rpCL1 from
F. hepatica, lacking some of the conformational epitopes that are
present in mature cathepsins from this trematode [31]. Neverthe-
less, this may be explained by considering that positive sera from
infected humans predominantly recognized the MM3 epitope
present in the rpCL1, as revealed by ELISA inhibition studies in
our laboratory (unpublished results). Thus, while in the MM3-
SERO ELISA, the MM3-recognized epitope on the cathepsins is
blocked by mAb MM3 during the process of antigen capture, in
the SeroFluke test this epitope is available to react with human
antibodies. The special preference for the MM3-epitope of the
antibodies present in serum from infected humans may also
explain the maximal specificity obtained in the present study, in
which all patients infected with other related or unrelated parasites
tested negative (Table 1). It is also possible that, in addition to the
immunodominant MM3 epitope, other epitopes not present in
mature cathepsin L from Fasciola contribute positively to
recognition of the antigen by human sera. This may be the case
of the B-cell epitopes, which were described in the prosegment
region of the Fasciola cathepsin L [42]. However, the relevance of
such epitopes as targets of anti-Fasciola serum antibodies in
humans has not yet been investigated.
With respect to the specificity of the LFIA, it should also be
noted that sera from patients infected with other liver food-borne
trematodes (e.g. Clonorchis sinensis and Opisthorchis viverrini) were not
available for study, which prevented us from establishing whether
these pathogens may provoke false positive results. Nevertheless, as
indicated above, since most of the anti-Fasciola antibodies are
directed to the specific MM3-recognized epitope, cross-reactions
with these species are not expected. This supposition is also
consistent with a previous study reporting no recognition of a
cathepsin L from Clonorchis sinensis by sera from patients infected
with Fasciola hepatica [43].
Another aspect of the SeroFluke test to be considered when
interpreting the results is that for some patients with large amounts
of anti-Fasciola antibodies, a decrease in the intensity of the control
Table 1. Reactivity of several types of human sera with Fasciola hepatica rpCL1.
Diseases Sera (n)
MM3-SERO
positive
MM3-SERO
doubtful
MM3-SERO
negative
SeroFluke
positive
SeroFluke
negative
Fasciolosis 39 38 1 0 39 0
Schistosomosis 27 0 0 27 0 27
Filariosis 20 0 0 20 0 20
Hydatidosis 9 0 0 9 0 9
Anisakiosis 15 0 0 15 0 15
Toxocariosis 22 0 0 22 0 22
Chagas’ disease 12 0 0 12 0 12
Other pathologies 59 0 0 59 0 59
Total 203 38 1 164 39 164
The reactivity of 203 human sera from patients with several parasitic diseases and other pathologies were compared using the MM3-SERO and SeroFluke tests.
doi:10.1371/journal.pntd.0001376.t001
Table 2. Reactivity of Fasciola positive sera measured with
MM3-SERO and SeroFluke tests.
MM3-SERO
OD ranks SeroFluke (AUs) TOTAL
0123 4 5
0.050–0.100 0 0 1 0 0 0 1
0.101–0.250 0 0 0 2 1 0 3
0.251–0.500 0 0 0 3 1 0 4
0.501–1.000 0 0 0 4 2 1 7
1.001–2.000 0 0 0 8 5 3 16
2.001–3.000 0 0 0 2 5 1 8
TOTAL 0011 91 453 9
doi:10.1371/journal.pntd.0001376.t002
A Serological LFIA for Fasciola
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Fasciola antibodies and the mAb MM3 immobilized in the control
line for the MM3 epitopes present on the rpCL1. Therefore, a
decrease in the signal in the control line often indicates that the sera
tested have a high concentration of anti-Fasciola antibodies, rather
than a failure of the device (for example due to incomplete liquid
migration). Since the SeroFluke test was designed for use without a
plastic housing, interpretation of the results is straightforward, as
liquid migration can be observed directly. This is even more evident
when testing whole blood samples because the migration of
haemoglobin clearly stains the absorbent pad red (see Fig. 4).
Nevertheless, if interpretation were doubtful, the test could be
repeated with a more diluted sample (e.g. 1/500–1/1000) which
would lead to an increase in signal intensity in the control line. The
presence of mAb MM3 in the control line, rather than any other
anti-rpCL1 antibody, may be advantageous for its use by trained
personnel in hospitals, as this design enables qualitative estimation
of the concentration of anti-Fasciola antibodies in serum by
comparing the intensity of colour in the positive and control lines.
In previous studies with the MM3-SERO test in sheep [27], we
have observed that such a test can be used to detect infections by
either F. hepatica or F. gigantica. In this study we did not have the
opportunity to test sera from patients infected with the latter
species. However, although experimental confirmation is required,
on the basis of our previous experience with the MM3-SERO
ELISA, it appears likely that the new SeroFluke test will also be
able to be used to detect human infections by F. gigantica.
In summary, we present a new highly stable, sensitive, and
specific LFIA for serodiagnosis of human fasciolosis. It is expected
that such a test will be useful for hospitals in hypoendemic regions
as well as in hyperendemic regions where POC testing is required.
Although serological tests cannot differentiate between current
and past infections, these methods are very useful for detecting
early infections, which may be then confirmed with data from
coprological tests, when the patent period of infection has been
reached, or with other complementary data. The suitability of the
SeroFluke test for detection of antibodies in animal species is also
being investigated.
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